TaskUs (NASDAQ:TASK) Bolsa

TASKUS INC-A

TaskUs

TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to the world's most innovative companies, helping its clients represent, protect and grow their brands. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.

TaskUs Inc

<p><strong>Grant Cardone</strong> isn't afraid of speaking harsh truths that can make people discover where they can improve. His book, "Be Obsessed Or Be Average," is filled with brutal truths, and he dropped a big one in chapter two.</p>
<p>"If you are living below your potential, it is only your fault."</p>
<p>This statement may be a hard pill to swallow for some people. It's easier and more comfortable to blame circumstances like your environment or upbringing. However, putting the entire blame on yourself suddenly puts you in control. This mentality can push you toward more ambitious goals for your career and finances.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>with $1,000 you can invest at just $0.30/share!</strong></a></strong></li>
<li><strong>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"><strong> </strong><strong>this is your last chance to become an investor for $0.80 per share.</strong></a></strong></li>
</ul>
<h2 class="wp-block-heading">Get Uncomfortable</h2>
<p>Tapping into your potential requires getting out of your comfort zone. Cardone says he's at his weakest when he settles into his comfort zone, but he's at his best when he is pushing boundaries.</p>
<p>Each person has a different path outside of their comfort zone. It may involve taking more action, doing something new, or moving. Cardone says that moving to a new town or city can force you to meet new people and dial in on your goals.</p>
<p>You will have to get uncomfortable often to tap into your potential. If you are not willing to change, your results will not change.</p>
<p><strong>Trending: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"><strong> </strong><strong>How do you compare</strong></a>?</strong></p>
<h2 class="wp-block-heading">Set Big Goals</h2>
<p>Our goals influence how much we work and what we achieve in our lives. Whether you want to advance in your career or build a larger portfolio, setting big goals can help you unlock more of your potential.</p>
<p>Cardone says it's good to set big goals, but you should never reduce them. Instead of reducing targets, Cardone believes that you should take more action to move closer to your high benchmark.&nbsp;</p>
<p>Big goals also make it easier to work harder and continue to push when others want to call it a day. Ambitious goals set the stage for incredible rewards, but you can only get the best rewards by working harder than your peers.&nbsp;</p>
<p><strong><em>See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age"><strong><em>If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</em></strong></a></em></strong></p>
<h2 class="wp-block-heading">Changing The Script</h2>
<p>You are responsible for where you are right now and how you choose to move forward. Being obsessed and fully embracing your goals can help you on the path to unlocking your potential.</p>
<p>However, it's important to avoid blaming people or circumstances when things don't go your way. High performers also shy away from any excuses and focus on how they can improve.</p>
<p>It's never too late to tap into your potential. Cardone was a drug addict in his early 20s, but he turned it around by taking responsibility for his life and committing to big goals.&nbsp;</p>
<p>Change isn't easy, but staying where you are may be more difficult in the long run.&nbsp;</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>Shark Tank's Kevin O'Leary called Missing Ring his biggest mistake — Don't repeat history—<a href="https://www.benzinga.com/money/big-tech-has-spent-billions-acquiring-ai-smart-home-startups-one-company-stands-to-benefit-and-has-already-made-10-million"><strong>invest in RYSE at just $1.90/share.</strong></a></strong></li>
<li><strong>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</strong></a></strong></li>
</ul>
<p><em><strong>Image: Shutterstock</strong></em></p>


Personal Finance

Grant Cardone Offers A Harsh Truth For Underperformers: 'If You Are Living Below Your Potential, It Is Only Your Fault'

<p><strong>Ross Gerber</strong>, CEO of <strong>Gerber Kawasaki Wealth &amp; Investment Management</strong>, has taken to social media to unload on the Trump administration&#8217;s trade policy and what he says is a lack of transparency from major companies like Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>).</p>
<p>&#8220;All companies should display the tariff cost as it is a tax on consumers,&#8221; Gerber <a href="https://x.com/GerberKawasaki/status/1917228510596177984">posted</a> last week on X, responding in part to recent comments by President <strong>Donald Trump</strong> suggesting that <a href="https://www.benzinga.com/markets/25/04/44944580/trump-says-tariffs-could-replace-income-tax-experts-warn-the-math-doesnt-work">tariffs could replace income taxes</a> for many Americans. &#8220;While they push this no income tax fantasy, the reality is this is the biggest tax HIKE on the average American family in modern history. Amazon should be transparent.&#8221;</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">All companies should display the tariff cost as it is a tax on consumers.  While they push this no income tax fantasy, the reality is this is the biggest tax HIKE on the average American family in modern history. Amazon should be transparent. <a href="https://twitter.com/search?q=%24AMZN&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$AMZN</a></p>
<p>&mdash; Ross Gerber (@GerberKawasaki) <a href="https://twitter.com/GerberKawasaki/status/1917228510596177984?ref_src=twsrc%5Etfw">April 29, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</strong></a></strong></li>
<li><strong>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"><strong> </strong><strong>this is your last chance to become an investor for $0.80 per share.</strong></a></strong></li>
</ul>
<h2 class="wp-block-heading">Amazon Denies Tariff Transparency Plan</h2>
<p>The post came on the same day a Punchbowl News <a href="https://punchbowl.news/article/tech/amazon-display-tariff-costs/">report</a> claimed Amazon was planning to show import charges on its main site. The White House jumped in quickly, with press secretary <strong>Karoline Leavitt</strong> <a href="https://www.benzinga.com/trading-ideas/movers/25/04/45067585/amazon-stock-tumbles-as-white-house-calls-tariff-visibility-plans-a-hostile-act">calling the alleged move</a> &#8220;a hostile and political act by Amazon.&#8221;&nbsp;</p>
<p>On its <a href="https://www.aboutamazon.com/news/retail/amazon-response-to-white-house-tariffs">website</a>, Amazon responded by saying no such plan existed for its main platform: &#8220;The team that runs our ultra low cost Amazon Haul store considered the idea of listing import charges on certain products. This was never approved and is not going to happen.&#8221; Haul is Amazon&#8217;s budget-focused unit that competes with sites like <strong>Temu</strong> and <strong>Shein</strong>.</p>
<p>President Trump even <a href="https://www.benzinga.com/markets/equities/25/04/45090925/trumps-call-to-jeff-bezos-over-amazons-tariff-display-plans-draws-criticism-from-peter-schiff-this-is-the-type-of-stuff-you-might-expect-to-see-in-china">called Amazon founder</a> and executive chairman <strong>Jeff Bezos</strong> to complain about the situation, later telling reporters, &#8220;He solved the problem very quickly. He did the right thing.&#8221;</p>
<p><strong>Trending: </strong><strong>Donald Trump just announced a $500 billion AI infrastructure deal — <a href="https://www.benzinga.com/money/seize-a-share-while-you-still-can-in-the-2-trillion-entertainment-market-with-elf-labs-at-just-2-25-share"><strong>here's how you can invest in the entertainment market's next big disruptor at $2.25 per share</strong></a></strong><strong>.</strong></p>
<h2 class="wp-block-heading">Backlash and Support Online</h2>
<p>Gerber's post sparked widespread debate online. One X user <a href="https://x.com/DaddyLoser/status/1917232950233506153">replied</a>, "This is awesome – now I know it's not made in the U.S. and I can shop elsewhere." Others called for even more accountability: "Be transparent and hold Republicans accountable for this mess," one person <a href="https://x.com/MissJilianne/status/1917231846859149439">posted</a>.</p>
<p>Several commenters compared the idea to how shipping companies add a fuel surcharge, calling tariff breakdowns on consumer products a &#8220;no-brainer.&#8221;</p>
<h2 class="wp-block-heading">Microsoft and the Bigger Picture</h2>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">Says a man who never built a company… <a href="https://t.co/HLgKUnRpvM">https://t.co/HLgKUnRpvM</a></p>
<p>&mdash; Ross Gerber (@GerberKawasaki) <a href="https://twitter.com/GerberKawasaki/status/1917954931459526879?ref_src=twsrc%5Etfw">May 1, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong><em>See Also: <a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"><strong><em>Invest Where It Hurts — And Help Millions Heal: Invest in Cytonics and help disrupt a $390B Big Pharma stronghold.</em></strong></a></em></strong></p>
<p>Gerber doubled down after U.S. Treasury Secretary <strong>Scott Bessent</strong> told <a href="https://finance.yahoo.com/news/treasury-secretary-scott-bessent-to-americas-biggest-ceos-stop-worrying-121627070.html">Yahoo Finance</a> that CEOs stop worrying about tariffs and get back to business.</p>
<p>&#8220;Says a man who never built a company&#8230;&#8221; Gerber <a href="https://x.com/GerberKawasaki/status/1917954931459526879">replied</a>.</p>
<p>In another <a href="https://x.com/GerberKawasaki/status/1917954441908727889">post</a>, he warned that Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) was hiking Xbox prices by up to $100 because of tariffs. &#8220;When tariffs hit the rest of society&#8230; this isn't going to go well,&#8221; he said.</p>
<p>With all sides weighing in, Gerber&#8217;s message has struck a nerve: if tariffs are here to stay, Americans deserve to see exactly how much they're paying and for what.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></strong></li>
<li><strong>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>with $1,000 you can invest at just $0.30/share!</strong></a></strong></li>
</ul>
<p><strong><em>Image: Shutterstock</em></strong></p>


News

AMZN

MSFT

Ross Gerber Blasts Amazon, Trump. Says The No Income Tax Is A Fantasy, 'Tariffs The Biggest Tax Hike On American Family In Modern History'

<p>Manitowoc Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTW#NYSE">MTW</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-06. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Manitowoc Co will report an <strong>earnings per share</strong> (EPS) of $-0.09.</p>
<p>The market awaits Manitowoc Co's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings Track Record</h3>
<p>In the previous earnings release, the company missed EPS by $0.02, leading to a 11.57% increase in the share price the following trading session.</p>
<p>Here's a look at Manitowoc Co's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.12</td>
<td>0.06</td>
<td>0.49</td>
<td>0.18</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.10</td>
<td>-0.08</td>
<td>0.25</td>
<td>0.14</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>12.0%</td>
<td>-10.0%</td>
<td>-5.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471835_0.png" alt="eps graph" /></p>
<h3>Manitowoc Co Share Price Analysis</h3>
<p>Shares of Manitowoc Co were trading at $8.5 as of May 02. Over the last 52-week period, shares are down 32.22%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Analyst Insights on Manitowoc Co</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Manitowoc Co.</p>
<p>With 1 analyst ratings, Manitowoc Co has a consensus rating of Neutral. The average one-year price target is $9.0, indicating a potential 5.88% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Wabash National, Twin Disc and Douglas Dynamics, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Wabash National, with an average 1-year price target of $14.0, suggesting a potential 64.71% upside.</li>
<li>Analysts currently favor an Buy trajectory for Twin Disc, with an average 1-year price target of $12.0, suggesting a potential 41.18% upside.</li>
<li>Analysts currently favor an Buy trajectory for Douglas Dynamics, with an average 1-year price target of $32.0, suggesting a potential 276.47% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>The peer analysis summary presents essential metrics for Wabash National, Twin Disc and Douglas Dynamics, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manitowoc Co</td>
<td>Neutral</td>
<td>0.03%</td>
<td>$95.20M</td>
<td>9.09%</td>
</tr>
<tr>
<td>Wabash National</td>
<td>Neutral</td>
<td>-30.08%</td>
<td>$42.96M</td>
<td>-0.53%</td>
</tr>
<tr>
<td>Twin Disc</td>
<td>Buy</td>
<td>23.19%</td>
<td>$21.68M</td>
<td>0.60%</td>
</tr>
<tr>
<td>Douglas Dynamics</td>
<td>Buy</td>
<td>6.93%</td>
<td>$35.74M</td>
<td>2.94%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Manitowoc Co ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Return on Equity.</p>
<h3>About Manitowoc Co</h3>
<p>Manitowoc Co Inc provides engineered lifting solutions. It designs and manufactures mobile telescopic cranes, tower cranes, lattice-boom crawler cranes, and boom trucks. It offers products under brand names such as Grove, Manitowoc, National Crane, Potain, Shuttlelift, and Manitowoc Crane Care. Its crane products serve dealers, rental companies, contractors, and government entities in diverse markets, including energy production/distribution and utility, petrochemical and industrial, infrastructure, and commercial/residential construction. Manitowoc has three reportable segments: the Americas, Europe and Africa, and the Middle East and Asia-Pacific. The Americas segment generates the majority of the revenue for the company.</p>
<h3>Understanding the Numbers: Manitowoc Co's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Manitowoc Co showcased positive performance, achieving a revenue growth rate of <strong>0.03%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Manitowoc Co's net margin excels beyond industry benchmarks, reaching <strong>9.51%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Manitowoc Co's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>9.09%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Manitowoc Co's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>3.3%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Manitowoc Co's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.68</strong>.</p>
<p><a href="https://www.benzinga.com/quote/MTW/earnings"><strong>To track all earnings releases for Manitowoc Co visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

Earnings Outlook For Manitowoc Co

<p>Park-Ohio Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PKOH#NASDAQ">PKOH</a>) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Park-Ohio Hldgs to report an <strong>earnings per share</strong> (EPS) of $0.83.</p>
<p>Investors in Park-Ohio Hldgs are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.05, leading to a 3.6% increase in the share price on the subsequent day.</p>
<p>Here's a look at Park-Ohio Hldgs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.62</td>
<td>0.89</td>
<td>0.94</td>
<td>0.79</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.67</td>
<td>1.07</td>
<td>1.02</td>
<td>0.85</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>-4.0%</td>
<td>6.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471820_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Park-Ohio Hldgs were trading at $20.61 as of May 02. Over the last 52-week period, shares are down 17.99%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/PKOH/earnings"><strong>To track all earnings releases for Park-Ohio Hldgs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


PKOH

What to Expect from Park-Ohio Hldgs's Earnings

<p>Commercial Vehicle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGI#NASDAQ">CVGI</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-06. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Commercial Vehicle Group to report an <strong>earnings per share</strong> (EPS) of $-0.14.</p>
<p>Investors in Commercial Vehicle Group are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company missed EPS by $0.08, which was followed by a 3.76% drop in the share price the next day.</p>
<p>Here's a look at Commercial Vehicle Group's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.07</td>
<td>0.04</td>
<td>0.17</td>
<td>0.20</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.15</td>
<td>-0.01</td>
<td>0.06</td>
<td>0.13</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>-22.0%</td>
<td>-16.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471807_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Commercial Vehicle Group were trading at $0.9803 as of May 02. Over the last 52-week period, shares are down 83.73%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CVGI/earnings"><strong>To track all earnings releases for Commercial Vehicle Group visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CVGI

Preview: Commercial Vehicle Group's Earnings

<p>comScore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-06. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that comScore will report an <strong>earnings per share</strong> (EPS) of $0.57.</p>
<p>The announcement from comScore is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company missed EPS by $1.73, leading to a 21.54% increase in the share price the following trading session.</p>
<p>Here's a look at comScore's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.46</td>
<td>-0.33</td>
<td>0.05</td>
<td>-0.41</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.27</td>
<td>-0.16</td>
<td>-1.19</td>
<td>-1.08</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>22.0%</td>
<td>41.0%</td>
<td>-33.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471794_0.png" alt="eps graph" /></p>
<h3>comScore Share Price Analysis</h3>
<p>Shares of comScore were trading at $5.24 as of May 02. Over the last 52-week period, shares are down 65.2%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SCOR/earnings"><strong>To track all earnings releases for comScore visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SCOR

comScore's Earnings Outlook

<p>Atomera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOM#NASDAQ">ATOM</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-06. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Atomera will report an <strong>earnings per share</strong> (EPS) of $-0.14.</p>
<p>The market awaits Atomera's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.02, leading to a 38.5% drop in the share price the following trading session.</p>
<p>Here's a look at Atomera's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.14</td>
<td>0</td>
<td>-0.15</td>
<td>-0.15</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.16</td>
<td>-0.17</td>
<td>-0.16</td>
<td>-0.19</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-38.0%</td>
<td>28.000000000000004%</td>
<td>13.0%</td>
<td>-17.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471783_0.png" alt="eps graph" /></p>
<h3>Market Performance of Atomera's Stock</h3>
<p>Shares of Atomera were trading at $5.02 as of May 02. Over the last 52-week period, shares are up 15.33%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/ATOM/earnings"><strong>To track all earnings releases for Atomera visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ATOM

Atomera's Earnings Outlook

<p><strong>WideOpenWest</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOW#NYSE">WOW</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that WideOpenWest will report an <strong>earnings per share</strong> (EPS) of $-0.19. </p>
<p>Investors in WideOpenWest are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.00, leading to a 0.0% drop in the share price on the subsequent day.</p>
<p>Here's a look at WideOpenWest's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.13</td>
<td>-0.10</td>
<td>-0.15</td>
<td>-0.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.13</td>
<td>-0.27</td>
<td>-0.13</td>
<td>-0.18</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>4.0%</td>
<td>0.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471769_0.png" alt="eps graph" /></p>
<h3>Market Performance of WideOpenWest's Stock</h3>
<p>Shares of WideOpenWest were trading at $4.49 as of May 02. Over the last 52-week period, shares are down 5.82%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/WOW/earnings"><strong>To track all earnings releases for WideOpenWest visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Peek at WideOpenWest's Future Earnings

<p><strong>Ranpak Hldgs</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACK#NYSE">PACK</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Ranpak Hldgs will report an <strong>earnings per share</strong> (EPS) of $-0.04. </p>
<p>Ranpak Hldgs bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS missed by $0.06 in the last quarter, leading to a 5.92% drop in the share price on the following day.</p>
<p>Here's a look at Ranpak Hldgs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.04</td>
<td>-0.04</td>
<td>-0.06</td>
<td>-0.07</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.10</td>
<td>-0.10</td>
<td>0.07</td>
<td>-0.10</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>0.0%</td>
<td>-9.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471761_0.png" alt="eps graph" /></p>
<h3>Market Performance of Ranpak Hldgs's Stock</h3>
<p>Shares of Ranpak Hldgs were trading at $4.42 as of May 02. Over the last 52-week period, shares are down 38.5%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/PACK/earnings"><strong>To track all earnings releases for Ranpak Hldgs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


PACK

Ranpak Hldgs's Earnings: A Preview

WIIM

Sotera Health shares are trading higher after Goldman Sachs upgraded the stock from Neutral to Buy and raised its price target from $14 to $17.

<p><strong>Myriad Genetics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Myriad Genetics will report an <strong>earnings per share</strong> (EPS) of $-0.06. </p>
<p>Investors in Myriad Genetics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company missed EPS by $0.00, which was followed by a 14.8% drop in the share price the next day.</p>
<p>Here's a look at Myriad Genetics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.03</td>
<td>0.02</td>
<td>-0.01</td>
<td>-0.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.03</td>
<td>0.06</td>
<td>0.05</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-15.0%</td>
<td>-1.0%</td>
<td>3.0%</td>
<td>21.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471745_0.png" alt="eps graph" /></p>
<h3>Myriad Genetics Share Price Analysis</h3>
<p>Shares of Myriad Genetics were trading at $7.56 as of May 02. Over the last 52-week period, shares are down 61.02%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MYGN/earnings"><strong>To track all earnings releases for Myriad Genetics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MYGN

Myriad Genetics's Earnings: A Preview

<p>Harmony Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Harmony Biosciences to report an <strong>earnings per share</strong> (EPS) of $1.09.</p>
<p>The market awaits Harmony Biosciences's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company beat EPS by $0.26, leading to a 9.47% drop in the share price the following trading session.</p>
<p>Here's a look at Harmony Biosciences's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.82</td>
<td>0.66</td>
<td>-0.06</td>
<td>0.62</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.08</td>
<td>1.03</td>
<td>1.05</td>
<td>0.88</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-9.0%</td>
<td>-19.0%</td>
<td>2.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471737_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Harmony Biosciences were trading at $30.32 as of May 02. Over the last 52-week period, shares are down 3.16%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Views on Harmony Biosciences</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Harmony Biosciences.</p>
<p>Harmony Biosciences has received a total of 12 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $54.5, the consensus suggests a potential 79.75% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Supernus Pharmaceuticals and ANI Pharmaceuticals, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Supernus Pharmaceuticals, with an average 1-year price target of $36.0, suggesting a potential 18.73% upside.</li>
<li>Analysts currently favor an Buy trajectory for ANI Pharmaceuticals, with an average 1-year price target of $84.29, suggesting a potential 178.0% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Supernus Pharmaceuticals and ANI Pharmaceuticals, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harmony Biosciences Hldgs</td>
<td>Buy</td>
<td>19.51%</td>
<td>$146.86M</td>
<td>7.88%</td>
</tr>
<tr>
<td>Supernus Pharmaceuticals</td>
<td>Neutral</td>
<td>5.99%</td>
<td>$148.06M</td>
<td>1.50%</td>
</tr>
<tr>
<td>ANI Pharmaceuticals</td>
<td>Buy</td>
<td>44.75%</td>
<td>$110.29M</td>
<td>-2.64%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Harmony Biosciences ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the lowest Return on Equity.</p>
<h3>Delving into Harmony Biosciences's Background</h3>
<p>Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.</p>
<h3>Harmony Biosciences: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Harmony Biosciences displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>19.51%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Harmony Biosciences's net margin is impressive, surpassing industry averages. With a net margin of <strong>24.58%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>7.88%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Harmony Biosciences's ROA excels beyond industry benchmarks, reaching <strong>5.13%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Harmony Biosciences's debt-to-equity ratio is below the industry average. With a ratio of <b>0.27</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/HRMY/earnings"><strong>To track all earnings releases for Harmony Biosciences visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


HRMY

Harmony Biosciences's Earnings: A Preview

<p>Financial giants have made a conspicuous bearish move on Maplebear. Our analysis of options history for Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) revealed 8 unusual trades.</p>
<p>Delving into the details, we found 12% of traders were bullish, while 62% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $199,200, and 3 were calls, valued at $272,000.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $45.0 to $50.0 for Maplebear over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Maplebear's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Maplebear's substantial trades, within a strike price spectrum from $45.0 to $50.0 over the preceding 30 days.</p>
<h3>Maplebear Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471736_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CART</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$8.3</td>
<td>$8.1</td>
<td>$8.2</td>
<td>$45.00</td>
<td>$157.4K</td>
<td>543</td>
<td align="right">300</td>
</tr>
<tr>
<td>CART</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$8.3</td>
<td>$8.1</td>
<td>$8.2</td>
<td>$45.00</td>
<td>$88.5K</td>
<td>543</td>
<td align="right">108</td>
</tr>
<tr>
<td>CART</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.6</td>
<td>$7.4</td>
<td>$7.6</td>
<td>$50.00</td>
<td>$48.6K</td>
<td>1.3K</td>
<td align="right">277</td>
</tr>
<tr>
<td>CART</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.8</td>
<td>$7.6</td>
<td>$7.8</td>
<td>$50.00</td>
<td>$43.6K</td>
<td>1.3K</td>
<td align="right">369</td>
</tr>
<tr>
<td>CART</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.7</td>
<td>$7.4</td>
<td>$7.6</td>
<td>$50.00</td>
<td>$38.0K</td>
<td>1.3K</td>
<td align="right">179</td>
</tr>
</tbody>
</table>
</p>
<h3>About Maplebear</h3>
<p>Maplebear (Instacart) operates a leading grocery delivery platform in the United States and Canada. The company partners with various regional and national grocers, which offer their selection of food and other goods to customers through Instacart's ubiquitous platform. Once an item is ordered through Instacart's site, the item is picked and delivered to the customer's home by one of the platform's 600,000 shoppers, who are classified as independent contractors. Instacart earns fees based on average order value and leverages its platform's high usage to sell advertising, mainly to consumer-packaged goods companies. Instacart currently has around 8 million monthly active users (or orderers) on its platform.</p>
<p>Following our analysis of the options activities associated with Maplebear, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Maplebear Standing Right Now?</h3>
<ul>
<li>With a trading volume of 5,993,897, the price of CART is up by 4.31%, reaching $47.17.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 92 days from now.</li>
</ul>
<h3>Expert Opinions on Maplebear</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $54.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Maplebear, which currently sits at a price target of $54.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Maplebear, targeting a price of $44.<br />
&#x2A; An analyst from JMP Securities downgraded its action to Market Outperform with a price target of $55.<br />
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $56.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Maplebear, targeting a price of $61. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Maplebear options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Markets

CART

Maplebear's Options Frenzy: What You Need to Know

<p>Deep-pocketed investors have adopted a bullish approach towards Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMAT usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Applied Mat. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 54% leaning bullish and 45% bearish. Among these notable options, 8 are puts, totaling $1,584,258, and 3 are calls, amounting to $92,140.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $135.0 and $175.0 for Applied Mat, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Applied Mat's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Applied Mat's significant trades, within a strike price range of $135.0 to $175.0, over the past month.</p>
<h3>Applied Mat Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471731_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$9.2</td>
<td>$9.0</td>
<td>$9.05</td>
<td>$150.00</td>
<td>$814.5K</td>
<td>2.1K</td>
<td>909</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$5.6</td>
<td>$5.4</td>
<td>$5.57</td>
<td>$155.00</td>
<td>$560.6K</td>
<td>499</td>
<td>1.1K</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$5.65</td>
<td>$5.5</td>
<td>$5.65</td>
<td>$155.00</td>
<td>$53.6K</td>
<td>499</td>
<td>14</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$22.35</td>
<td>$21.5</td>
<td>$22.13</td>
<td>$175.00</td>
<td>$44.2K</td>
<td>2.4K</td>
<td>20</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$13.3</td>
<td>$12.75</td>
<td>$13.3</td>
<td>$145.00</td>
<td>$37.2K</td>
<td>1.0K</td>
<td>30</td>
</tr>
</tbody>
</table>
</p>
<h3>About Applied Mat</h3>
<p>Applied Materials Inc is the largest semiconductor wafer fabrication equipment, or WFE, manufacturer in the world. Applied Materials has a broad portfolio spanning nearly every corner of the WFE ecosystem. Specifically, Applied Materials holds a market share leadership position in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.</p>
<p>After a thorough review of the options trading surrounding Applied Mat, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Applied Mat</h3>
<ul>
<li>With a volume of 2,302,788, the price of AMAT is up 0.73% at $156.24. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 10 days.</li>
</ul>
<h3>What Analysts Are Saying About Applied Mat</h3>
<p>4 market experts have recently issued ratings for this stock, with a consensus target price of $178.75.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Applied Mat with a target price of $195.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Applied Mat, targeting a price of $170.<br />
&#x2A; An analyst from B of A Securities persists with their Buy rating on Applied Mat, maintaining a target price of $190.<br />
&#x2A; An analyst from Barclays has decided to maintain their Equal-Weight rating on Applied Mat, which currently sits at a price target of $160. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Applied Mat, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


AMAT

Market Whales and Their Recent Bets on AMAT Options

<p>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-06. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Evotec to report an <strong>earnings per share</strong> (EPS) of $-0.24.</p>
<p>Evotec bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS missed by $0.11 in the last quarter, leading to a 0.0% drop in the share price on the following day.</p>
<p>Here's a look at Evotec's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.01</td>
<td>-0.08</td>
<td>-0.06</td>
<td>-0.100</td>
<td>-0.03</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.12</td>
<td>-0.12</td>
<td>-0.29</td>
<td>-0.065</td>
<td></td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>10.0%</td>
<td>10.0%</td>
<td>-4.0%</td>
<td>-5.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471727_0.png" alt="eps graph" /></p>
<h3>Tracking Evotec's Stock Performance</h3>
<p>Shares of Evotec were trading at $4.29 as of May 02. Over the last 52-week period, shares are down 17.9%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/EVO/earnings"><strong>To track all earnings releases for Evotec visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Preview: Evotec

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Strategy</strong>.</p>
<p>Looking at options history for Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) we detected 234 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 43% with bearish.</p>
<p>From the overall spotted trades, 66 are puts, for a total amount of $5,269,103 and 168, calls, for a total amount of $13,737,995.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $10.0 to $800.0 for Strategy during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Strategy's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Strategy's whale activity within a strike price range from $10.0 to $800.0 in the last 30 days. </p>
<h3>Strategy Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471726_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MSTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$352.6</td>
<td>$351.9</td>
<td>$352.6</td>
<td>$710.00</td>
<td>$1.0M</td>
<td>42</td>
<td align="right">30</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$47.1</td>
<td>$46.6</td>
<td>$47.0</td>
<td>$500.00</td>
<td>$470.0K</td>
<td>3.8K</td>
<td align="right">113</td>
</tr>
<tr>
<td>MSTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$166.75</td>
<td>$165.5</td>
<td>$166.75</td>
<td>$410.00</td>
<td>$333.5K</td>
<td>47</td>
<td align="right">20</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$379.2</td>
<td>$377.5</td>
<td>$378.4</td>
<td>$10.00</td>
<td>$264.8K</td>
<td>1.2K</td>
<td align="right">28</td>
</tr>
<tr>
<td>MSTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$33.9</td>
<td>$33.7</td>
<td>$33.7</td>
<td>$380.00</td>
<td>$168.5K</td>
<td>871</td>
<td align="right">276</td>
</tr>
</tbody>
</table>
</p>
<h3>About Strategy</h3>
<p>Strategy is a bitcoin treasury company and a provider of business intelligence services. It is designed to provide investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed-income instruments. The company also provide industry AI-powered enterprise analytics software.</p>
<p>Having examined the options trading patterns of Strategy, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Strategy</h3>
<ul>
<li>With a trading volume of 9,875,095, the price of MSTR is down by -1.48%, reaching $388.55.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 87 days from now.</li>
</ul>
<h3>What The Experts Say On Strategy</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $510.8.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from HC Wainwright &amp; Co. downgraded its action to Buy with a price target of $480.<br />
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Strategy, targeting a price of $464.<br />
&#x2A; An analyst from HC Wainwright &amp; Co. persists with their Buy rating on Strategy, maintaining a target price of $521.<br />
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Strategy, which currently sits at a price target of $475.<br />
&#x2A; Consistent in their evaluation, an analyst from Cantor Fitzgerald keeps a Overweight rating on Strategy with a target price of $614. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Strategy with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


MSTR

Strategy Unusual Options Activity

<p><strong>Hyster Yale</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HY#NYSE">HY</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Hyster Yale will report an <strong>earnings per share</strong> (EPS) of $0.49. </p>
<p>Hyster Yale bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company beat EPS by $0.08, which was followed by a 2.84% increase in the share price the next day.</p>
<p>Here's a look at Hyster Yale's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.39</td>
<td>1.97</td>
<td>2.11</td>
<td>2.14</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.47</td>
<td>0.97</td>
<td>3.58</td>
<td>2.93</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>5.0%</td>
<td>-16.0%</td>
<td>24.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471719_0.png" alt="eps graph" /></p>
<h3>Performance of Hyster Yale Shares</h3>
<p>Shares of Hyster Yale were trading at $40.33 as of May 02. Over the last 52-week period, shares are down 32.53%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/HY/earnings"><strong>To track all earnings releases for Hyster Yale visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Glimpse of Hyster Yale's Earnings Potential

<p>Across the recent three months, 10 analysts have shared their insights on CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $10.8, a high estimate of $15.00, and a low estimate of $7.00. Highlighting a 0.83% decrease, the current average has fallen from the previous average price target of $10.89. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471692_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive CryoPort. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Richard Baldry</td>
<td>Roth MKM</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$10.00</td>
<td>-</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CryoPort. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CryoPort compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of CryoPort's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into CryoPort's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CYRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on CryoPort analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>About CryoPort</h2>
<p>CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.</p>
<h3>Understanding the Numbers: CryoPort's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> CryoPort's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>3.97%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-34.73%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> CryoPort's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-5.49%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> CryoPort's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-2.94%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> CryoPort's debt-to-equity ratio is below the industry average at <strong>0.68</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

CYRX

Forecasting The Future: 10 Analyst Projections For CryoPort

<p>Lineage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Lineage and provided 12-month price targets. The average target is $64.92, accompanied by a high estimate of $75.00 and a low estimate of $49.00. Highlighting a 13.32% decrease, the current average has fallen from the previous average price target of $74.90. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471673_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Lineage among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Goldfarb</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$49.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$59.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Nicholas Thillman</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Greg McGinniss</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$56.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$59.00</td>
<td>-</td>
</tr>
<tr>
<td>Ronald Kamdem</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Craig Mailman</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Greg McGinniss</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$74.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$74.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Nicholas Thillman</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Alex Goldfarb</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Lineage. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Lineage compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Lineage's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Lineage's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LINE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Lineage analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Lineage</h2>
<p>Lineage Inc is a temperature-controlled warehouse real estate investment trust. It operates an interconnected global temperature-controlled warehouse network, comprising approximately millions of square feet across several warehouses predominantly located in densely populated critical-distribution markets across North America, Asia-Pacific, and Europe. The company's reportable segments are Global Warehousing, which utilizes the company's industrial real estate properties to provide temperature-controlled warehousing services to its customers, and Global Integrated Solutions, which complements Global Warehousing with specialized cold-chain services. Maximum revenue is generated from the Global Warehousing segment. Geographically, the company derives its key revenue from the United States.</p>
<h3>Unraveling the Financial Story of Lineage</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Lineage's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately <strong>-2.71%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Lineage's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>0.15%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Lineage's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>0.02%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Lineage's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.01%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Lineage's debt-to-equity ratio is below the industry average. With a ratio of <b>0.83</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


LINE

What 12 Analyst Ratings Have To Say About Lineage

<p>Throughout the last three months, 5 analysts have evaluated OSI Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSIS#NASDAQ">OSIS</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $239.0, a high estimate of $260.00, and a low estimate of $210.00. This current average reflects an increase of 7.42% from the previous average price target of $222.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471658_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The standing of OSI Systems among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Glynn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Jeff Martin</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$245.00</td>
<td>$224.00</td>
</tr>
<tr>
<td>Josh Nichols</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$255.00</td>
<td>$221.00</td>
</tr>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Seth Seifman</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$225.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to OSI Systems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of OSI Systems compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for OSI Systems's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of OSI Systems's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OSIS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on OSI Systems analyst ratings.</strong></a></p>
<h2>All You Need to Know About OSI Systems</h2>
<p>OSI Systems Inc is a designer and manufacturer of electronic systems and components for businesses in the homeland security, healthcare, defense, and aerospace markets. The firm is organized in three business segments: Security, which derives maximum revenue, provides security and inspection systems; Healthcare, which provides patient monitoring, diagnostic, cardiology, ventilation systems and defibrillators; and Optoelectronics and Manufacturing, which provides specialized electronic components and manufacturing services for the Security and Healthcare segments and external original equipment manufacturers. Majority of the firm's revenue is generated in the United States, and the rest from Mexico, Europe, the Middle East, and Africa, and the Asia Pacific regions.</p>
<h3>Breaking Down OSI Systems's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> OSI Systems's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>5.84%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>9.26%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> OSI Systems's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>4.82%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> OSI Systems's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.95%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> OSI Systems's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.72</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


OSIS

Beyond The Numbers: 5 Analysts Discuss OSI Systems Stock

Legal

Press Releases

Kuehn Law Encourages Investors of TaskUs, Inc. to Contact Law Firm

TaskUs, Inc. to Announce Fourth-Quarter and Full-Year 2024 Financial Results on February 26, 2025

Grabar Law Office Is Investigating Claims on Behalf of Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Extreme Networks, Inc. (NASDAQ: EXTR); MGP Ingredients, Inc. (NASDAQ: MGPI); and TaskUs, Inc. (NASDAQ: TASK)

TaskUs Announces Fiscal Fourth-Quarter and Full-Year 2024 Results

TaskUs Launches Agentic AI Consulting Practice to Lead Businesses through the AI Era

TaskUs to Present at the 2025 Morgan Stanley Technology, Media & Telecom Conference on March 4, 2025

Short Sellers

TASKUS ALERT: Bragar Eagel & Squire, P.C. is Investigating TaskUs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Comments

TaskUs

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL